SOLE试验:绝经后乳腺癌延长辅助来曲唑间歇与连续用药比较
SOLE是一项多中心开放标签随机3期试验,纳入4851例绝经后激素受体阳性淋巴结阳性乳腺癌患者,比较延长辅助来曲唑间歇与连续用药。
要点
- 延长辅助来曲唑间歇用药未改善无病生存。
- 两组不良事件相似,3-5级高血压间歇组24% vs 连续组21%。
- 结果支持特定患者临时停药的安全性。
核心结论
- 绝经后激素受体阳性乳腺癌患者延长使用间歇来曲唑与连续使用相比未改善无病生存。
研究设计与样本
- 多中心开放标签随机平行3期试验,在22个国家240个中心纳入4851例绝经后激素受体阳性淋巴结阳性可手术乳腺癌患者。
- 主要终点为无病生存,按意向治疗原则用分层log-rank检验分析。
主要发现
- 最常见3-5级不良事件为高血压(间歇组584/2417[24%] vs 连续组517/2411[21%])和关节痛(136[6%] vs 151[6%])。
- 3-5级中枢神经系统缺血性脑血管事件54例(间歇组24[1%] vs 连续组30[1%]),中枢神经系统出血16例(9[<1%] vs 7[<1%]),心脏缺血40例(19[1%] vs 21[1%])。
- 试验治疗期间共23例(<1%)死亡(间歇组13/2417[<1%] vs 连续组10/2411[<1%])。
临床怎么用
- 延长辅助内分泌治疗中,间歇来曲唑方案未显示优于连续用药,不应常规用于改善无病生存。
- 对于需要临时停药的患者,SOLE试验结果支持短期治疗中断的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared with continuous use of letrozole in postmenopausal women. METHODS: We did the multicentre, open-label, randomised, parallel, phase 3 SOLE trial in 240 centres (academic, primary, secondary, and tertiary care centres) in 22 countries. We enrolled postmenopausal women of any age with hormone receptor-positive, lymph node-positive, and operable breast cancer for which they had undergone local treatment (surgery with or without radiotherapy) and had completed 4-6 years of adjuvant endocrine therapy. They had to be clinically free of breast cancer at enrolment and without evidence of recurrent disease at any time before randomisation. We randomly assigned women (1:1) to treatment groups of either continuous use of letrozole (2·5 mg/day orally for 5 years) or intermittent use of letrozole (2·5 mg/day orally for 9 months followed by a 3-month break in years 1-4 and then 2·5 mg/day during all 12 months of year 5). Randomisation was done by principal investigators or designee at respective centres through the internet-based system of the International Breast Cancer Study Group, was stratified by type of previous endocrine therapy (aromatase inhibitors only vs selective oestrogen receptor modulators only vs both therapies), and used permuted block sizes of four and institutional balancing. No one was masked to treatment assignment. The primary endpoint was disease-free survival, analysed by the intention-to-treat principle using a stratified log-rank test. All patients in the intention-to-treat population who initiated protocol treatment during their period of trial participation were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT00553410, and EudraCT, number 2007-001370-88; and long-term follow-up of patients is ongoing. FINDINGS: Between Dec 5, 2007, and Oct 8, 2012, 4884 women were enrolled and randomised after exclusion of patients at a non-adherent centre, found to have inadequate documentation of informed consent, immediately withdrew consent, or randomly assigned to intervention groups in error. 4851 women comprised the intention-to-treat population that compared extended intermittent letrozole use (n=2425) with continuous letrozole use (n=2426). After a median follow-up of 60 months (IQR 53-72), disease-free survival was 85·8% (95% CI 84·2-87·2) in the intermittent letrozole group compared with 87·5% (86·0-88·8) in the continuous letrozole group (hazard ratio 1·08, 95% CI 0·93-1·26; p=0·31). Adverse events were reported as expected and were similar between the two groups. The most common grade 3-5 adverse events were hypertension (584 [24%] of 2417 in the intermittent letrozole group vs 517 [21%] of 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]). 54 patients (24 [1%] in the intermittent letrozole group and 30 [1%] in the continuous letrozole group) had grade 3-5 CNS cerebrovascular ischaemia, 16 (nine [<1%] vs seven [<1%]) had grade 3-5 CNS haemorrhage, and 40 (19 [1%] vs 21 [1%]) had grade 3-5 cardiac ischaemia. In total, 23 (<1%) of 4851 patients died while on trial treatment (13 [<1%] of 2417 patients in the intermittent letrozole group vs ten [<1%] of 2411 in the continuous letrozole group). INTERPRETATION: In postmenopausal women with hormone receptor-positive breast cancer, extended use of intermittent letrozole did not improve disease-free survival compared with continuous use of letrozole. An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them. FUNDING: Novartis and the International Breast Cancer Study Group.
引用
- Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 29158011. doi:10.1016/S1470-2045(17)30715-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。